RU2012144555A - Конъюгированный фактор свертывания крови viii - Google Patents

Конъюгированный фактор свертывания крови viii Download PDF

Info

Publication number
RU2012144555A
RU2012144555A RU2012144555/15A RU2012144555A RU2012144555A RU 2012144555 A RU2012144555 A RU 2012144555A RU 2012144555/15 A RU2012144555/15 A RU 2012144555/15A RU 2012144555 A RU2012144555 A RU 2012144555A RU 2012144555 A RU2012144555 A RU 2012144555A
Authority
RU
Russia
Prior art keywords
fviii
pharmaceutical composition
conjugate
bond
composition according
Prior art date
Application number
RU2012144555/15A
Other languages
English (en)
Russian (ru)
Inventor
Вильям Генри
Original Assignee
Кантаб Биофармасьютикалз Пэтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2012144555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кантаб Биофармасьютикалз Пэтентс Лимитед filed Critical Кантаб Биофармасьютикалз Пэтентс Лимитед
Publication of RU2012144555A publication Critical patent/RU2012144555A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2012144555/15A 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii RU2012144555A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB1007357.5 2010-04-30
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (1)

Publication Number Publication Date
RU2012144555A true RU2012144555A (ru) 2014-06-10

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012144555/15A RU2012144555A (ru) 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii

Country Status (26)

Country Link
US (1) US20130150302A1 (https=)
EP (1) EP2563402A1 (https=)
JP (1) JP5870088B2 (https=)
KR (1) KR20130055619A (https=)
CN (1) CN102939108A (https=)
AP (1) AP2012006575A0 (https=)
AU (1) AU2011247147B2 (https=)
BR (1) BR112012027590A2 (https=)
CA (1) CA2797058A1 (https=)
CL (1) CL2012003039A1 (https=)
CO (1) CO6660443A2 (https=)
CR (1) CR20120579A (https=)
EA (1) EA201290938A1 (https=)
EC (1) ECSP12012314A (https=)
GB (2) GB201007357D0 (https=)
IL (1) IL222566A (https=)
MX (1) MX2012012683A (https=)
MY (1) MY160922A (https=)
NI (1) NI201200160A (https=)
NZ (1) NZ603939A (https=)
PE (1) PE20130254A1 (https=)
PH (1) PH12012502150A1 (https=)
RU (1) RU2012144555A (https=)
SG (1) SG184906A1 (https=)
WO (1) WO2011135307A1 (https=)
ZA (1) ZA201208989B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2789085C2 (ru) * 2018-05-18 2023-01-30 Чжэнчжоу Дженсайнсес Инк. Улучшенный белок слияния fviii и его применение
US12440572B2 (en) 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2789085C2 (ru) * 2018-05-18 2023-01-30 Чжэнчжоу Дженсайнсес Инк. Улучшенный белок слияния fviii и его применение
US12440572B2 (en) 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof

Also Published As

Publication number Publication date
CL2012003039A1 (es) 2014-01-24
MY160922A (en) 2017-03-31
JP5870088B2 (ja) 2016-02-24
HK1173946A1 (en) 2013-05-31
IL222566A0 (en) 2012-12-31
IL222566A (en) 2017-12-31
ZA201208989B (en) 2014-02-26
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB201220667D0 (en) 2013-01-02
AP2012006575A0 (en) 2012-12-31
ECSP12012314A (es) 2013-05-31
SG184906A1 (en) 2012-11-29
PE20130254A1 (es) 2013-03-16
GB201007357D0 (en) 2010-06-16
GB2492935B (en) 2014-04-30
CR20120579A (es) 2013-04-25
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
CN102939108A (zh) 2013-02-20
GB2492935A (en) 2013-01-16
JP2013525414A (ja) 2013-06-20
GB2492935B8 (en) 2014-10-29
CO6660443A2 (es) 2013-04-30
WO2011135307A1 (en) 2011-11-03
EP2563402A1 (en) 2013-03-06
MX2012012683A (es) 2013-04-03
NI201200160A (es) 2013-04-19
KR20130055619A (ko) 2013-05-28
AU2011247147B2 (en) 2014-09-18
CA2797058A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
RU2012144555A (ru) Конъюгированный фактор свертывания крови viii
RU2012144554A (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
JP2013525414A5 (https=)
RU2010147813A (ru) Конъюгаты фактора ix с увеличенным временем полужизни
JP7490563B2 (ja) Ｉｌ－２コンジュゲート
JP2011519833A5 (https=)
EP1792927B1 (en) Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
US8859499B2 (en) Method of enhancing efficacy of blood transfusions
JP6732056B2 (ja) 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EA023208B1 (ru) Фармацевтические композиции, которые содержат имидазохинолин(амины) и их производные, пригодные для местного введения
JP6799823B2 (ja) ポリ（ｌ−アルギニン）セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス
KR20110020779A (ko) 도세탁셀 고분자 유도체 및 그 제조 방법 및 그 용도
CN106714820A (zh) 选择素及icam/vcam肽配体偶联物
RU2015134583A (ru) Фармацевтические композиции, содержащие доноры нитроксила
WO2015067791A1 (en) Relaxin prodrugs
US20220289903A1 (en) Polymer and composition from renewable source
RU2012105579A (ru) Способ конъюгирования полимера с белком, конъюгат, полученный указанным способом, композиция и лекарственное средство на его основе и способ лечения с их помощью
WO2009142328A1 (ja) カンプトテシン高分子誘導体及びその用途
JP2024517355A5 (https=)
JP6735759B2 (ja) カンプトテシン類高分子誘導体を含有する医薬組成物
CN112424239B (zh) 高分子化合物及使用了该高分子化合物的细胞内化合物导入促进剂
JP6797182B2 (ja) カンプトテシン類高分子誘導体を含有する医薬製剤
RU2002102232A (ru) Конъюгаты эритропоэтина и полиэтиленгликоля (второе название "Производные эритропоэтина")
JP2026067320A (ja) 医薬組成物
RU2015147544A (ru) Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160527